The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

MAPK Signaling

See how Bayer is investigating MAPK signaling across the oncology pipeline

Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.

 

MAPK Signaling

  • Rat sarcoma (RAS) is an upstream protein in the mitogen-activated protein kinase (MAPK) signaling pathway1

  • RAS is activated by several stimuli that primarily involve the formation of complexes comprising autophosphorylated growth factor receptors, the adapter protein growth factor receptor–bound protein 2 (GRB2), and the exchange factor son of sevenless homolog 1 (SOS1)1

  • Specifically, the signaling adapter protein GRB2 facilitates the binding of receptor tyrosine kinases (RTKs) or anchoring proteins to SOS1/2, which activates RAS paralogs2

  • The activated SOS1 subsequently induces the guanosine diphosphate (GDP) and guanosine triphosphate (GTP) exchange of RAS paralogs and thereby activates the MAPK cascade2

  • SOS1 inhibition is a promising therapeutic strategy for diseases involving the dysregulation of the MAPK pathway3

MAPK-signaling

Tumor Types

Gastrointestinal cancer (colorectal, esophageal, pancreatic)
Lung cancer
Solid tumors

Related Compounds

SOS1 inhibitor (BAY 3498264)
KRAS-G12D inhibitor (BAY 3771249)

Bayer's Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.